Cangrelor Versus Clopidogrel on a Background of Unfractionated
Heparin (from CHAMPION PHOENIX)

J 2017

Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX)

VADUGANATHAN, M., R.A. HARRINGTON, G.W. STONE, P.G. STEG, C.M. GIBSON et. al.

Základní údaje

Originální název

Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX)

Autoři

VADUGANATHAN, M., R.A. HARRINGTON, G.W. STONE, P.G. STEG, C.M. GIBSON, C.W. HAMM, M.J. PRICE, E.N. DELIARGYRIS, J. PRATS, K.W. MAHAFFEY, H.D. WHITE a D.L. BHATT

Vydání

American Journal of Cardiology, BRIDGEWATER, EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC, 2017, 0002-9149

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.171

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.amjcard.2017.06.042

UT WoS

000412626000001

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 4. 2018 18:56, Soňa Böhmová

Anotace

V originále

Cangrelor is approved for use during percutaneous coronary intervention (PCI) and is administered with different parenteral anticoagulants. We examined the efficacy and safety of cangrelor in the subgroup of patients who received unfractionated heparin (UFH) during PCI in the modified intention-to-treat population of the randomized CHAMPION PHOENIX trial (cangrelor vs clopidogrel; n = 10,939). The primary efficacy end point was the composite of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis (ST) at 48 hours. The key secondary efficacy end point was ST. UFH was used in 69.2% (7,569/10,939) of patients. In the UFH subgroup, cangrelor reduced the primary composite efficacy end point at 48 hours compared with clopidogrel (4.8% vs 5.9%; odds ratio [OR] 0.80 [0.65 to 0.98]; p = 0.03). Cangrelor consistently reduced ST at 2 hours (0.7% vs 1.3%; OR 0.56 [0.35 to 0.90]; p = 0.01) and 48 hours (0.9% vs 1.4%; OR 0.70 [0.45 to 1.07]; p = 0.10). There was no difference in GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries)-defined severe or life-threatening bleeding (0.1% vs 0.1%; OR 1.24 [0.33 to 4.61]; p = 0.75) or blood transfusion requirement at 48 hours (0.4% vs 0.2%; OR 1.87 [0.83 to 4.21]; p = 0.12). In conclusion, cangrelor reduces early ischemic periprocedural complications without increasing severe bleeding compared with clopidogrel in patients undergoing PCI with UFH. (C) 2017 Elsevier Inc. All rights reserved.

Citovat

VADUGANATHAN, M., R.A. HARRINGTON, G.W. STONE, P.G. STEG, C.M. GIBSON, C.W. HAMM, M.J. PRICE, E.N. DELIARGYRIS, J. PRATS, K.W. MAHAFFEY, H.D. WHITE a D.L. BHATT. Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). American Journal of Cardiology. BRIDGEWATER: EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC, 2017, roč. 120, č. 7, s. 1043-1048. ISSN 0002-9149. Dostupné z: https://dx.doi.org/10.1016/j.amjcard.2017.06.042.

@article{1400050,
   author = {Vaduganathan, M. and Harrington, R.A. and Stone, G.W. and Steg, P.G. and Gibson, C.M. and Hamm, C.W. and Price, M.J. and Deliargyris, E.N. and Prats, J. and Mahaffey, K.W. and White, H.D. and Bhatt, D.L. and Kala, Petr},
   article_location = {BRIDGEWATER},
   article_number = {7},
   doi = {http://dx.doi.org/10.1016/j.amjcard.2017.06.042},
   language = {eng},
   issn = {0002-9149},
   journal = {American Journal of Cardiology},
   title = {Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX)},
   url = {http://dx.doi.org/10.1016/j.amjcard.2017.06.042},
   volume = {120},
   year = {2017}
}

TY  - JOUR
ID  - 1400050
AU  - Vaduganathan, M. - Harrington, R.A. - Stone, G.W. - Steg, P.G. - Gibson, C.M. - Hamm, C.W. - Price, M.J. - Deliargyris, E.N. - Prats, J. - Mahaffey, K.W. - White, H.D. - Bhatt, D.L. - Kala, Petr
PY  - 2017
TI  - Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX)
JF  - American Journal of Cardiology
VL  - 120
IS  - 7
SP  - 1043-1048
EP  - 1043-1048
PB  - EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
SN  - 00029149
UR  - http://dx.doi.org/10.1016/j.amjcard.2017.06.042
L2  - http://dx.doi.org/10.1016/j.amjcard.2017.06.042
N2  - Cangrelor is approved for use during percutaneous coronary intervention (PCI) and is administered with different parenteral anticoagulants. We examined the efficacy and safety of cangrelor in the subgroup of patients who received unfractionated heparin (UFH) during PCI in the modified intention-to-treat population of the randomized CHAMPION PHOENIX trial (cangrelor vs clopidogrel; n = 10,939). The primary efficacy end point was the composite of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis (ST) at 48 hours. The key secondary efficacy end point was ST. UFH was used in 69.2% (7,569/10,939) of patients. In the UFH subgroup, cangrelor reduced the primary composite efficacy end point at 48 hours compared with clopidogrel (4.8% vs 5.9%; odds ratio [OR] 0.80 [0.65 to 0.98]; p = 0.03). Cangrelor consistently reduced ST at 2 hours (0.7% vs 1.3%; OR 0.56 [0.35 to 0.90]; p = 0.01) and 48 hours (0.9% vs 1.4%; OR 0.70 [0.45 to 1.07]; p = 0.10). There was no difference in GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries)-defined severe or life-threatening bleeding (0.1% vs 0.1%; OR 1.24 [0.33 to 4.61]; p = 0.75) or blood transfusion requirement at 48 hours (0.4% vs 0.2%; OR 1.87 [0.83 to 4.21]; p = 0.12). In conclusion, cangrelor reduces early ischemic periprocedural complications without increasing severe bleeding compared with clopidogrel in patients undergoing PCI with UFH. (C) 2017 Elsevier Inc. All rights reserved.
ER  -

VADUGANATHAN, M., R.A. HARRINGTON, G.W. STONE, P.G. STEG, C.M. GIBSON, C.W. HAMM, M.J. PRICE, E.N. DELIARGYRIS, J. PRATS, K.W. MAHAFFEY, H.D. WHITE a D.L. BHATT. Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). \textit{American Journal of Cardiology}. BRIDGEWATER: EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC, 2017, roč.~120, č.~7, s.~1043-1048. ISSN~0002-9149. Dostupné z: https://dx.doi.org/10.1016/j.amjcard.2017.06.042.

Podrobný výpis o publikaci